Dyne Therapeutics, Inc. Operating Expenses
Dyne Therapeutics, Inc. (DYN) reported Operating Expenses of $181.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-07-29
- Dyne Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $181.66M, a 56.89% increase year-over-year.
- Dyne Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $125.28M, a 2.37% increase year-over-year.
- Dyne Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $116.13M, a 19.59% increase year-over-year.
- Dyne Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $113.89M, a 7.79% increase year-over-year.
- Dyne Therapeutics, Inc. operating expenses for fiscal 2025 was $468.18M, a 36.15% increase from fiscal 2024.
- Dyne Therapeutics, Inc. operating expenses for fiscal 2024 was $343.89M, a 42.01% increase from fiscal 2023.
- Dyne Therapeutics, Inc. operating expenses for fiscal 2023 was $242.16M, a 41.65% increase from fiscal 2022.
- Dyne Therapeutics, Inc. operating expenses for fiscal 2022 was $170.96M, a 13.96% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $181.66M 10-Q · filed 2026-07-29 | $306.94M 10-Q · filed 2026-07-29 | $423.07M derived: sum of 3 quarters · filed 2026-07-29 | $536.96M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $125.28M 10-Q · filed 2026-05-11 | $241.41M derived: sum of 2 quarters · filed 2026-05-11 | $355.30M derived: sum of 3 quarters · filed 2026-05-11 | $471.09M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $116.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $230.02M derived: sum of 2 quarters · filed 2026-03-02 | $345.81M derived: sum of 3 quarters · filed 2026-07-29 | $468.18M 10-K · filed 2026-03-02 |
| 2025-09-30 | $113.89M 10-Q · filed 2025-11-05 | $229.68M derived: sum of 2 quarters · filed 2026-07-29 | $352.06M 10-Q · filed 2025-11-05 | $449.16M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $115.79M 10-Q · filed 2026-07-29 | $238.16M 10-Q · filed 2026-07-29 | $335.27M derived: sum of 3 quarters · filed 2026-07-29 | $440.93M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $122.37M 10-Q · filed 2026-05-11 | $219.48M derived: sum of 2 quarters · filed 2026-05-11 | $325.14M derived: sum of 3 quarters · filed 2026-05-11 | $397.10M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $97.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $202.77M derived: sum of 2 quarters · filed 2026-03-02 | $274.73M derived: sum of 3 quarters · filed 2026-03-02 | $343.89M 10-K · filed 2026-03-02 |
| 2024-09-30 | $105.66M 10-Q · filed 2025-11-05 | $177.62M derived: sum of 2 quarters · filed 2025-11-05 | $246.78M 10-Q · filed 2025-11-05 | $314.47M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $71.96M 10-Q · filed 2025-07-28 | $141.12M 10-Q · filed 2025-07-28 | $208.81M derived: sum of 3 quarters · filed 2026-03-02 | $271.08M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $69.16M 10-Q · filed 2025-05-08 | $136.84M derived: sum of 2 quarters · filed 2026-03-02 | $199.12M derived: sum of 3 quarters · filed 2026-03-02 | $265.85M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $67.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $129.96M derived: sum of 2 quarters · filed 2026-03-02 | $196.70M derived: sum of 3 quarters · filed 2026-03-02 | $242.16M 10-K · filed 2026-03-02 |
| 2023-09-30 | $62.27M 10-Q · filed 2024-11-12 | $129.01M derived: sum of 2 quarters · filed 2024-11-12 | $174.47M 10-Q · filed 2024-11-12 | $214.62M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $66.74M 10-Q · filed 2024-08-12 | $112.20M 10-Q · filed 2024-08-12 | $152.34M derived: sum of 3 quarters · filed 2025-02-27 | $194.62M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $45.46M 10-Q · filed 2024-05-02 | $85.61M derived: sum of 2 quarters · filed 2025-02-27 | $127.89M derived: sum of 3 quarters · filed 2025-02-27 | $180.64M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $40.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $82.42M derived: sum of 2 quarters · filed 2025-02-27 | $135.18M derived: sum of 3 quarters · filed 2025-02-27 | $170.96M 10-K · filed 2025-02-27 |
| 2022-09-30 | $42.28M 10-Q · filed 2023-10-30 | $95.03M derived: sum of 2 quarters · filed 2023-10-30 | $130.82M 10-Q · filed 2023-10-30 | $182.78M derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | $52.76M 10-Q · filed 2023-08-03 | $88.54M 10-Q · filed 2023-08-03 | $140.50M derived: sum of 3 quarters · filed 2023-08-03 | $183.26M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $35.78M 10-Q · filed 2023-05-11 | $87.74M derived: sum of 2 quarters · filed 2023-05-11 | $130.51M derived: sum of 3 quarters · filed 2023-05-11 | $160.67M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $51.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $94.73M derived: sum of 2 quarters · filed 2023-03-02 | $124.89M derived: sum of 3 quarters · filed 2023-03-02 | $150.03M 10-K · filed 2023-03-02 |
| 2021-09-30 | $42.77M 10-Q · filed 2022-11-03 | $72.93M derived: sum of 2 quarters · filed 2022-11-03 | $98.06M 10-Q · filed 2022-11-03 | $126.67M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $30.16M 10-Q · filed 2022-08-04 | $55.30M 10-Q · filed 2022-08-04 | $83.90M derived: sum of 3 quarters · filed 2022-08-04 | $97.42M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $25.13M 10-Q · filed 2022-05-02 | $53.73M derived: sum of 2 quarters · filed 2022-05-02 | $67.25M derived: sum of 3 quarters · filed 2022-05-02 | $75.93M derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | $28.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $42.12M derived: sum of 2 quarters · filed 2022-03-10 | $50.80M derived: sum of 3 quarters · filed 2022-03-10 | $58.65M 10-K · filed 2022-03-10 |
| 2020-09-30 | $13.52M 10-Q · filed 2021-11-04 | $22.20M derived: sum of 2 quarters · filed 2021-11-04 | $30.05M 10-Q · filed 2021-11-04 | $35.52M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $8.68M 10-Q · filed 2021-08-05 | $16.53M 10-Q · filed 2021-08-05 | $22.00M derived: sum of 3 quarters · filed 2021-08-05 | $25.63M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $7.85M 10-Q · filed 2021-05-06 | $13.32M derived: sum of 2 quarters · filed 2021-05-06 | $16.95M derived: sum of 3 quarters · filed 2021-05-06 | |
| 2019-12-31 | $5.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $9.10M derived: sum of 2 quarters · filed 2021-03-04 | $13.83M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $3.63M 10-Q · filed 2020-11-05 | $8.36M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |